Form 4: BioAtla CEO Awarded 430,000 Restricted Stock Units

BioAtla, Inc. CEO Jay M. Short, PhD, was granted 430,000 restricted stock units, aligning executive incentives with long-term shareholder value.

Summary

• BioAtla, Inc. CEO and Director, Jay M. Short, PhD, was awarded 430,000 shares of common stock in the form of a time-based restricted stock unit (RSU) award on March 11, 2026.
• The RSU award has a grant price of $0.
• The vesting schedule for the RSU award is 25% of the total shares on March 11, 2027.
• Following the initial vesting, 6.25% of the total shares will vest quarterly on the last day of each May, August, November, and February.
• Vesting is contingent upon Dr. Short's continued service to the company through each applicable vesting date.
• Following this transaction, Dr. Short's direct beneficial ownership stands at 2,659,603 shares, with additional indirect ownership through various entities including a spouse, irrevocable gift trusts, and LLCs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it strengthens the alignment between the CEO's long-term incentives and shareholder value, a common and effective compensation strategy.

Positives

• The grant of 430,000 restricted stock units to the CEO aligns management's long-term interests with those of shareholders.
• RSUs are a common form of equity compensation designed to incentivize executive retention and performance over a multi-year period.

Negatives

• The RSU award does not represent an immediate cash investment by the CEO into the company's stock.
• Future vesting of these shares will result in dilution for existing shareholders as new shares are issued.

Risks

• The vesting of the RSU award is subject to the reporting person's continued service, meaning the shares could be forfeited if employment ceases before the applicable vesting dates.

Future Outlook

The RSU award with its multi-year vesting schedule indicates a strategic move to retain key executive talent and align management's long-term interests with the company's future performance and shareholder value creation.

Management Comments

• The RSU award is designed to vest over time, subject to continued service, reinforcing the company's commitment to long-term executive retention and performance incentives.

Industry Context

StockSavvy.ai notes that restricted stock unit awards are a standard and widely accepted form of executive compensation across the biotechnology and pharmaceutical industries. This practice aims to incentivize long-term commitment and align executive interests with shareholder value creation, particularly in sectors requiring sustained research and development efforts.

Comparison to Industry Standards

• The use of time-based restricted stock units (RSUs) for executive compensation is a common practice, comparable to compensation structures seen at companies like Amgen, Gilead Sciences, and Biogen, which frequently utilize equity awards to retain and motivate senior leadership.
• The vesting schedule, with an initial cliff followed by quarterly vesting, is typical for RSU grants in the biotech sector, similar to programs at companies such as Moderna or Pfizer, designed to ensure sustained executive engagement over several years.
• The $0 grant price for RSUs is standard, as these awards represent a right to receive shares upon vesting, rather than an option to purchase at a set price, aligning with common equity compensation models in high-growth industries.

Related Party Transactions

• Indirect beneficial ownership through spouse.
• Indirect beneficial ownership through Carolyn Short 2020 Irrevocable Gift Trust.
• Indirect beneficial ownership through Jay Short 2020 Irrevocable Gift Trust.
• Indirect beneficial ownership through Capia IP, LLC.
• Indirect beneficial ownership through Himalaya Parent LLC, where the reporting person and spouse are managers.

Stakeholder Impact

• Shareholders: Potential future dilution upon vesting of RSUs, but also increased alignment of CEO's interests with long-term shareholder value.
• Employees: Reinforces the company's commitment to executive retention, potentially signaling stability at the top.

Next Steps

• First tranche of 25% of the RSU award vests on March 11, 2027.
• Subsequent quarterly vesting of 6.25% of the RSUs will occur on the last day of May, August, November, and February, contingent on continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) rather than a fundamental business update or a direct open-market purchase/sale. While it aligns management incentives with long-term shareholder value, it does not provide new information warranting a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals.

Keywords

BioAtla, BCAB, SEC Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Ownership, Jay M. Short, Equity Award, Corporate Governance